Biologic
Adalimumab
n=1881
Certolizumab
n=236
Golimumab
n=3
Infliximab
n=1861
Natalizumab
n=10
Ustekinumab
n=6
Vedolizumabb
n=20
Healthcare resource utilization
Patients with an inpatient hospitalization, n (%)
Baseline 570 (30.30) 73 (30.93) 0 (0) 613 (32.94) 3 (30.00) 3 (50.00) 10 (50.00)
Follow-up 275 (14.62) 54 (22.88) 0 (0) 263 (14.13) 0 (0) 0 (0) 3 (15.00)
Inpatient hospitalizations per patient, mean (SD)
Baseline 0.43 (0.78) 0.49 (0.89) 0 (0) 0.49 (0.88) 0.30 (0.48) 1.67 (2.25) 0.75 (0.85)
Follow-up 0.20 (0.56) 0.38 (0.85) 0 (0) 0.19 (0.56) 0 (0) 0 (0) 0.20 (0.52)
Patients with an ED visit, n (%)
Baseline 775 (41.20) 103 (43.64) 1 (33.33) 776 (41.70) 5 (50.00) 5 (83.33) 7 (35.00)
Follow-up 513 (27.27) 71 (30.09) 0 (0) 534 (28.69) 2 (20.00) 4 (66.67) 8 (40.00)
ED visits per patient, mean (SD)
Baseline 0.70 (1.11) 0.97 (2.70) 0.33 (0.58) 0.79 (1.33) 0.60 (0.70) 2.67 (2.16) 0.70 (1.13)
Follow-up 0.48 (1.15) 0.72 (3.31) 0 (0) 0.47 (1.00) 0.30 (0.67) 0.83 (0.75) 0.60 (0.82)
Patients with an outpatient visit, n (%)
Baseline 1877 (99.79) 236 (100) 3 (100) 1849 (99.36) 10 (100) 6 (100) 20 (100)
Follow-up 1868 (99.31) 233 (98.73) 3 (100) 1861(100) 10 (100) 6 (100) 20 (100)
Outpatient visits per patient, mean (SD)
Baseline 16.14 (11.73) 17.80 (12.75) 27.00 (17.44) 17.27 (12.84) 19.60 (9.88) 28.00 (15.63) 26.30 (22.25)
Follow-up 15.05 (13.00) 17.67 (13.39) 21.33 (7.09) 21.94 (13.23) 30.10 (13.53) 36.83 (27.65) 31.05 (22.45)
Costs, US$ 2015, mean (SD)
Inpatient hospitalization costs per patient
Baseline 8894.42 (26 648.77) 10 492.38 (29 166.85) 0 (0) 11 683.65 (35 928.48) 11 534.97 (18 983.79) 147 170.98 (285 747.82) 12 223.66 (14 058.01)
Follow up 4199.85 (17 030.25) 8080.19 (20 565.86) 0 (0) 3918.12 (17 834.50) 0 (0) 0 (0) 2364.72 (9008.96)
ED visits costs per patient
Baseline 1274.60 (2779.19) 1567.64 (3762.28) 1342.98 (2326.11) 1440.24 (3560.70) 727.93 (1028.85) 3569.68 (3046.72) 843.65 (1465.20)
Follow-up 1044.72 (4028.97) 1170.06 (4209.37) 0 (0) 847.99 (2368.77) 835.27 (1761.05) 2093.74 (2450.65) 1701.89 (4383.03)
Outpatient visits costs per patient
Baseline 7803.99 (12 149.21) 9005.12 (14 665.55) 8373.34 (6598.27) 17 394.02 (29 709.42) 14 632.14 (19 283.66) 29 120.35 (11 429.60) 12 596.98 (14 273.08)
Follow-up 4521.96 (5521.87) 5303.72 (6673.90) 9391.97 (6967.49) 10 070.37 (16 781.91) 10 592.61 (4679.90) 7828.56 (8860.66) 31 374.63 (20 248.29)
Total medical costs per patient
Baseline 19 837.11 (32 052.82) 23 518.26 (39 755.76) 18 411.21 (21 619.98) 32 576.31 (46 598.06) 27 805.68 (23 835.03) 194 206.71 (306 934.63) 26 778.24 (21 696.95)
Follow-up 10 984.94 (21 216.69) 15 960.54 (24 596.59) 9391.97 (6967.49) 16 073.35 (26 619.55) 12 653.75 (7669.55) 10 614.10 (10 895.98) 37 013.93 (22 603.98)
Pharmacy costs per patient
Baseline 4798.63 (5700.39) 6086.57 (9669.60) 11 828.47 (8887.83) 4162.05 (5015.65) 23 474.93 (18 983.13) 8210.59 (9432.24) 7606.23 (12 849.52)
Follow-up 42 141.90 (12 709.15) 36 211.70 (12 773.02) 53 677.88 (20 737.84) 42 504.25 (33 689.20) 73 353.16 (41 617.06) 116 161.44 (40 545.36) 44 250.79 (44 740.47)
Medical and pharmacy costs per patient
Baseline 24 635.74 (32 763.09) 29 604.84 (42 484.50) 30 239.68 (13 482.39) 36 738.35 (47 014.77) 51 280.61 (18 410.06) 202 417.30 (315 989.78) 34 384.47 (29 555.64)
Follow-up 53 126.84 (25 940.69) 52 172.23 (28 908.94) 63 069.84 (27 048.67) 58 577.60 (43 762.09) 86 006.90 (47 308.21) 126 775.54 (43 885.33) 81 264.72 (45 114.80)